64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)

NCT04726033 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Prostate Cancer

Interventions

DRUG: 64Cu-DOTA-TLX592

Sponsor

Telix Pharmaceuticals (Innovations) Pty Limited